Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Once-monthly Oral Ibandronate Improves Biomechanical Determinants Of Bone Strength In Women With Postmenopausal Osteoporosis.

E. Lewiecki, T. Keaveny, D. Kopperdahl, H. Genant, K. Engelke, T. Fuerst, A. Kivitz, R. Davies, L. Fitzpatrick
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
CONTEXT Bone strength and fracture resistance are determined by bone mineral density (BMD) and structural, mechanical, and geometric properties of bone. DESIGN, SETTING, AND OBJECTIVES: This randomized, double-blind, placebo-controlled outpatient study evaluated effects of once-monthly oral ibandronate on hip and lumbar spine BMD and calculated strength using quantitative computed tomography (QCT) with finite element analysis (FEA) and dual-energy x-ray absorptiometry (DXA) with hip structural analysis (HSA). PARTICIPANTS Participants were women aged 55-80 yr with BMD T-scores -2.0 or less to -5.0 or greater (n = 93). INTERVENTION Oral ibandronate 150 mg/month (n = 47) or placebo (n = 46) was administered for 12 months. OUTCOME MEASURES The primary end point was total hip QCT BMD change from baseline; secondary end points included other QCT BMD sites, FEA, DXA, areal BMD, and HSA. All analyses were exploratory, with post hoc P values. RESULTS Ibandronate increased integral total hip QCT BMD and DXA areal BMD more than placebo at 12 months (treatment differences: 2.2%, P = 0.005; 2.0%, P = 0.003). FEA-derived hip strength to density ratio and femoral, peripheral, and trabecular strength increased with ibandronate vs. placebo (treatment differences: 4.1%, P < 0.001; 5.9%, P < 0.001; 2.5%, P = 0.011; 3.5%, P = 0.003, respectively). Ibandronate improved vertebral, peripheral, and trabecular strength and anteroposterior bending stiffness vs. placebo [7.1% (P < 0.001), 7.8% (P < 0.001), 5.6% (P = 0.023), and 6.3% (P < 0.001), respectively]. HSA-estimated femoral narrow neck cross-sectional area and moment of inertia and outer diameter increased with ibandronate vs. placebo (respectively 3.6%, P = 0.003; 4.0%, P = 0.052; 2.2%, P = 0.049). CONCLUSIONS Once-monthly oral Ibandronate for 12 months improved hip and spine BMD measured by QCT and DXA and strength estimated by FEA of QCT scans.
This paper references
Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography.
R. Crawford (2003)
Severity of vertebral fracture reflects deterioration of bone microarchitecture
H. Genant (2006)
Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.
N. Watts (2004)
Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A Perspective
M. Bouxsein (2008)
Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure
R. Recker (2008)
Impact direction from a fall influences the failure load of the proximal femur as much as age-related bone loss
T. Pinilla (2006)
Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women.
G.J. van Londen (2008)
Risedronate Preserves Trabecular Architecture and Increases Bone Strength in Vertebra of Ovariectomized Minipigs as Measured by Three‐Dimensional Microcomputed Tomography
B. Borah (2002)
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
S. Silverman (2006)
Effects of ibandronate on bone quality: preclinical studies.
F. Bauss (2007)
Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
K. Uusi-Rasi (2005)
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies*
S. Harris (2008)
Structural Determinants of Vertebral Fracture Risk
L. J. Melton (2007)
Structural Trends in the Aging Femoral Neck and Proximal Shaft: Analysis of the Third National Health and Nutrition Examination Survey Dual‐Energy X‐Ray Absorptiometry Data
T. J. Beck (2000)
Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions.
K. Engelke (2008)
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study
R. Recker (2003)
Structural and remodeling indices in the cancellous bone of the proximal femur across adulthood.
H. Tsangari (2007)
A biomechanical perspective on bone quality.
C. Hernandez (2006)
Alterations of Cortical and Trabecular Architecture Are Associated With Fractures in Postmenopausal Women, Partially Independent of Decreased BMD Measured by DXA: The OFELY Study
E. Sornay-Rendu (2007)
Finite Element Analysis of the Proximal Femur and Hip Fracture Risk in Older Men
E. Orwoll (2009)
Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis
T. M. Keaveny (2007)
Effect of oral ibandronate on hip structure: results from the BONE study [abstract Su323]
T Fuerst (2006)
How can bone turnover modify bone strength independent of bone mass?
C. Hernandez (2008)
Comparison of DXA hip structural analysis with volumetric QCT.
T. Beck (2009)
Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals.
L. Mosekilde (1990)
Cancellous bone remodeling in type i (postmenopausal) osteoporosis: Quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels
Erik F. Eriksen (1990)
Long‐Term Protective Effects of Zoledronic Acid on Cancellous and Cortical Bone in the Ovariectomized Rat
J. Gasser (2008)
Effect of Hormone Replacement, Alendronate, or Combination Therapy on Hip Structural Geometry: A 3‐Year, Double‐Blind, Placebo‐Controlled Clinical Trial
S. Greenspan (2005)
Improved prediction of proximal femoral fracture load using nonlinear finite element models.
J. Keyak (2001)
Volumetric quantitative computed tomography of the proximal femur: relationships linking geometric and densitometric variables to bone strength. Role for compact bone
V. Bousson (2006)
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
M. Mcclung (2001)
Cortical and Trabecular Load Sharing in the Human Vertebral Body
S. Eswaran (2006)
An anatomic coordinate system of the femoral neck for highly reproducible BMD measurements using 3D QCT.
Yan Kang (2005)
Is cortical bone hip? What determines cortical bone properties?
S. Epstein (2007)
A Biomechanical Analysis of the Effects of Resorption Cavities on Cancellous Bone Strength
C. Hernandez (2006)
Femoral Bone Strength and Its Relation to Cortical and Trabecular Changes After Treatment With PTH, Alendronate, and Their Combination as Assessed by Finite Element Analysis of Quantitative CT Scans
T. M. Keaveny (2008)
68 Regional Differences of Spinal BMD Changes After One Year Once-Monthly Ibandronate as Measured by 3D QCT
K. Engelke (2009)
HSA: beyond BMD with DXA.
S. Bonnick (2007)
A hierarchical 3D segmentation method and the definition of vertebral body coordinate systems for QCT of the lumbar spine
André Mastmeyer (2006)

This paper is referenced by
Can hip fracture prediction in women be estimated beyond bone mineral density measurement alone?
P. Geusens (2010)
J. J. Ward (2014)
Effect of Ibandronate on Bending Strength and Toughness on Rodent Cortical bone ; possible implications for fracture prevention
R. Wallace (2015)
Use of DXA‐based finite element analysis of the proximal femur in a longitudinal study of hip fracture
K. Naylor (2013)
Skeletal assessment with finite element analysis: relevance, pitfalls and interpretation
G. Campbell (2017)
Efficacy and Safety of Monthly 150 mg Oral Ibandronate in Women with Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Y. Lee (2011)
Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.
O. Bock (2012)
Age-Dependence of Femoral Strength in White Women and Men
T. Keaveny (2010)
Fracture Risk Prediction by Non-BMD DXA Measures: the 2015 ISCD Official Positions Part 1: Hip Geometry.
S. Broy (2015)
Assessment of finite element models for prediction of osteoporotic fracture.
Yeokyeong Lee (2019)
Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats.
M. Shahnazari (2010)
The association between lower Hounsfield units of the upper instrumented vertebra and proximal junctional kyphosis in adult spinal deformity surgery with a minimum 2-year follow-up.
P. Duan (2020)
Fifty years of bisphosphonates: What are their mechanical effects on bone?
D. Burr (2020)
Les apports de la DXA en dehors de la mesure de la densité minérale osseuse
K. Briot (2013)
Atlas of Postmenopausal Osteoporosis
R. Rizzoli (2010)
Hip Fracture Discrimination Based on Statistical Multi-parametric Modeling (SMPM)
J. Carballido-Gamio (2019)
Biomechanical modeling of proximal femur : development of finite element models to simulate fractures
Janne Koivumäki (2013)
Prevention and treatment of postmenopausal osteoporosis
A. Neuprez (2010)
Quantitative computed tomography assessment of bone mineral density after 2 years’ oral bisphosphonate treatment in postmenopausal osteoarthritis patients who underwent total knee arthroplasty
J. Lee (2013)
Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene
F. Cosman (2013)
Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis
R. Rizzoli (2011)
Fracture ostéoporotique chez l'homme : estimation du risque en tomodensitométrie à la hanche
J. Lellouche (2015)
Quantifying the material and structural determinants of bone strength.
M. Bouxsein (2009)
Advanced CT based In Vivo Methods for the Assessment of Bone Density, Structure, and Strength
K. Engelke (2013)
A comparison of DXA and CT based methods for estimating the strength of the femoral neck in post-menopausal women
M. Danielson (2012)
Influence of 3D QCT scan protocol on the QCT-based finite element models of human vertebral cancellous bone.
Yongtao Lu (2014)
Effect of ibandronate on bending strength and toughness of rodent cortical bone
T. Savaridas (2015)
Femoral strength in osteoporotic women treated with teriparatide or alendronate.
T. M. Keaveny (2012)
Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology.
P. Zysset (2015)
Vertebral Strength Changes as Assessed by Finite Element Analysis
T. Mawatari (2016)
Association of incident hip fracture with the estimated femoral strength by finite element analysis of DXA scans in the Osteoporotic Fractures in Men (MrOS) study
L. Yang (2017)
Mapping anisotropy of the proximal femur for enhanced image based finite element analysis.
W. S. Enns-Bray (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar